# PEDMARK (pedmark) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pedmark

> The FDA approved PEDMARK (pedmark), sponsored by FENNEC PHARMACEUTICALS INC. (FENC), on September 20, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is PEDMARK (pedmark) FDA approved?

Yes. The FDA approved PEDMARK (pedmark), sponsored by FENNEC PHARMACEUTICALS INC. (FENC), on September 20, 2022. SEC Form 10-K: "On September 20, 2022, we received approval from the FDA for PEDMARK® (sodium thiosulfate injection)." [Calendar and source filings](https://sec-api.dev/pdufa/pedmark)

Source: SEC Form 10-K, accession 0001558370-25-003710, https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm (retrieved 2026-11-12). Last confirmed 2025-11-19. Cite: https://sec-api.dev/pdufa/pedmark#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | PEDMARK (pedmark) |
| Codes |  |
| Sponsor | FENNEC PHARMACEUTICALS INC. (FENC) https://sec-api.dev/companies/fenc/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | orphan |

## Timeline

### September 20, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-12-20, last confirmed 2025-11-19.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-113915): "PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI®." https://www.sec.gov/Archives/edgar/data/1211583/000110465925113915/tm2531627d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-113646): "PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in" https://www.sec.gov/Archives/edgar/data/1211583/000110465925113646/tm2531509d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-113646): "PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI®." https://www.sec.gov/Archives/edgar/data/1211583/000110465925113646/tm2531509d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-112912): "PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI®." https://www.sec.gov/Archives/edgar/data/1211583/000110465925112912/tm2531308d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-112912): "PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and" https://www.sec.gov/Archives/edgar/data/1211583/000110465925112912/tm2531308d1_ex99-2.htm
- SEC Form 10-K (accession 0001558370-25-003710): "On September 20, 2022, we received approval from the FDA for PEDMARK® (sodium thiosulfate injection)." https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-002599): "Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSIÒ." https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/fencf-20250310xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000715): "Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSIÒ." https://www.sec.gov/Archives/edgar/data/1211583/000155837025000715/fencf-20250207xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-130855): "Further, PEDMARK received FDA approval in September 2022 and" https://www.sec.gov/Archives/edgar/data/1211583/000110465924130855/tm2431725d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-130854): "Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K." https://www.sec.gov/Archives/edgar/data/1211583/000110465924130854/tm2431725d1_ex99-1.htm

### December 2, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2/3.
- First seen 2025-12-02, last confirmed 2025-12-02.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-117697): "2025 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection)" https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_ex99-1.htm

### December 2, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2/3.
- First seen 2025-12-02, last confirmed 2025-12-02.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-117697): "2025 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection)" https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_ex99-1.htm

### September 17, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-09-17, last confirmed 2026-09-17.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-108565): "Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK® in Japan AT SIOP 2026" https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917xex99d1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pedmark.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PEDMARK (pedmark) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pedmark

```bibtex
@misc{secapidev_pdufa_pedmark_20261116,
  title        = {PEDMARK (pedmark) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pedmark}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pedmark_20261116","title":"PEDMARK (pedmark) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pedmark","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
